W.L. Gore and Associates announced the FDA has granted a new indication for prevention of recurrent ischemic stroke for its patent foramen ovale closure device. The expanded approval of the device ...

CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

FLAGSTAFF, Ariz., March 11, 2021 /CNW/ -- W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England ...

Five-year results from the randomized REDUCE trial show a continued benefit of patent foramen ovale (PFO) closure compared with antiplatelet therapy alone for the prevention of cryptogenic stroke.

CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) ...

(MENAFN- GlobeNewsWire - Nasdaq) The PFO closure device market is driven by a shift to minimally invasive solutions and patient-centric care. Opportunities lie in transcatheter methods, bioresorbable ...

W.L. Gore & Associates (Gore) has launched a multicenter, prospective, randomized placebo- and sham-controlled investigational study that will evaluate the safety and efficacy of transcatheter closure ...